Literature DB >> 7840293

Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs.

J R Teerlink1, J P Carteaux, U Sprecher, B M Löffler, M Clozel, J P Clozel.   

Abstract

Endothelin (ET) is a potent vasoconstrictor that may be involved in a number of cardiovascular disorders, although its role in normal hemodynamics remains unclear. Twenty-two anesthetized open-chest dogs were instrumented for measurement of systemic and pulmonary hemodynamics, cardiac output, coronary blood flow, and cardiac contractility. Big ET induced peripheral and coronary vasoconstriction, which occurred before significant elevations in plasma ET and which was nearly completely blocked by bosentan, a new nonpeptidic mixed (ETA and ETB) ET receptor antagonist. Bosentan also prevented the peripheral dilatation caused by the specific ETB receptor agonist, sarafotoxin S6c, but did not prevent the peripheral vasoconstriction induced by angiotensin II. Bosentan alone had no significant hemodynamic effect in the normal anesthetized dog, although it did induce a reactive increase in the plasma level of ET-1 and ET-3. This study demonstrates that, despite blocking both ETA and ETB receptors, bosentan alone had no hemodynamic effect, suggesting that ET does not play a major role in the normal hemodynamic status of anesthetized dogs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7840293     DOI: 10.1152/ajpheart.1995.268.1.H432

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 2.  Crosstalk between endothelin and nitric oxide in the control of vascular tone.

Authors:  M Lavallée; M Takamura; R Parent; E Thorin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 3.  Endothelins: pathophysiology and treatment implications in chronic heart failure.

Authors:  John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-12

4.  The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

Authors:  C Plumpton; C J Ferro; W G Haynes; D J Webb; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  Bosentan, a novel synthetic mixed-type endothelin receptor antagonist, attenuates acute gastric mucosal lesions induced by indomethacin and HCl in the rat: role of endogenous endothelin-1.

Authors:  K Matsumaru; H Kashimura; M Hassan; A Nakahara; T Hayashi; R Iwata; K Goto; H Muto; N Tanaka; H Fukutomi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

6.  Endothelin receptor blockade in canine oleic acid-induced lung injury.

Authors:  Ives Hubloue; Dominique Biarent; Sophia Abdel Kafi; Gilbert Bejjani; Christian Mélot; Robert Naeije; Marc Leeman
Journal:  Intensive Care Med       Date:  2003-05-07       Impact factor: 17.440

Review 7.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

8.  Paracrine renal endothelin system in rats with liver cirrhosis.

Authors:  B Hocher; R Zart; F Diekmann; P Rohmeiss; A Distler; H H Neumayer; C Bauer; P Gross
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.